Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% - Should You Sell?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) fell 6.1% on Thursday . The stock traded as low as $21.30 and last traded at $21.20. 227,654 shares changed hands during trading, a decline of 73% from the average session volume of 837,960 shares. The stock had previously closed at $22.57.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Price Performance

The stock has a market cap of $1.21 billion, a PE ratio of -28.45 and a beta of -2.37. The stock's fifty day moving average is $24.80 and its 200-day moving average is $31.75.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently added to or reduced their stakes in GPCR. ANTIPODES PARTNERS Ltd raised its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at $34,000. FNY Investment Advisers LLC acquired a new stake in Structure Therapeutics during the 4th quarter worth $40,000. Finally, Virtus ETF Advisers LLC lifted its position in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.